Ross Stores, Inc. vs Tempus AI — how do they compare? Ross Stores, Inc. trades at $225.95 (market cap $73.25B), while Tempus AI trades at $61.16 (market cap $11.67B). The key difference: Ross Stores, Inc. is far larger — about 6.3× Tempus AI's market cap, and Ross Stores, Inc. pays a 0.78% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| ROST | TEM | |
|---|---|---|
Market Cap | $73.25B | $11.67B |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $255.23 | $103.25 |
52-Week Low | $144.67 | $41.55 |
Enterprise Value | $73.70B | $12.30B |
Dividend Yield | 0.78% | — |
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $229.31, down 0.6% on the day, showing bearish technical signals despite strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.66 beating expectations by 36%. Revenue growth accelerated to 13% in Q2 2026, with comparable store sales surging 10% driven by increased traffic and margin expansion. The stock faces technical resistance near $234 while maintaining strong analyst support with a $271.33 consensus price target.
ROST presents a compelling growth story with robust fundamentals but faces near-term technical headwinds. The company's value-focused retail strategy resonates with cost-conscious consumers, driving consistent earnings outperformance. Key risks include competitive pressures in off-price retail and macroeconomic sensitivity. With 64% of analysts maintaining buy ratings and a 19% upside to consensus targets, the stock offers growth potential for investors comfortable with current technical weakness.
Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats despite negative profitability, with a P/S of 7.99 and P/B of 26.23. Recent catalysts include FDA clearance for an AI ECG product and a $9.5 million ARPA-H award for autonomous AI in cardiology (Business Wire, September 9, 2026).
Outlook remains positive given analyst consensus and growth in precision medicine, but risks include sustained losses, high valuation multiples, and cash burn. The consensus price target is $69.11, implying potential upside, though investors must weigh the company's unprofitability against its innovation pipeline and market position.
Trailing returns across standard periods
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →